IDH1 and cancer: Given that IDH1-mutant cancers are exquisitely reliant on NAMPT for their NAD supplies (as they downregulate NAPRT expression), NAMPT inhibitors were found to exhibit remarkable antitumor activity against IDH1-mutant glioma and fibrosarcoma xenografts [53].